A fixed-dose combination topical preparation designed for the comprehensive management of mixed dermatological infections, particularly those involving fungi, bacteria, and associated inflammation. Miconazole is an imidazole antifungal, Mometasone is a potent topical corticosteroid, and Nadifloxacin is a topical fluoroquinolone antibiotic. This combination is specifically formulated to address the complex etiology of conditions like infected eczema, infected tinea, and other inflammatory dermatoses with secondary infection.
Adult: Apply a thin film to the affected area once or twice daily, as directed by the physician. Typical duration is 2 weeks, maximum 4 weeks.
Note: 1. Wash and dry the affected area thoroughly. 2. Take a small amount of cream on clean fingertips. 3. Gently apply a thin layer to cover the affected area. 4. Rub in lightly until absorbed. 5. Wash hands after application unless hands are the treated area. 6. Do not cover with occlusive dressings unless specifically advised by the doctor.
This combination exerts a triple action: 1) Miconazole inhibits ergosterol synthesis in fungal cell membranes, leading to increased permeability and cell death. 2) Mometasone binds to glucocorticoid receptors, inhibiting inflammatory mediators (prostaglandins, leukotrienes), reducing vasodilation, edema, and itching. 3) Nadifloxacin inhibits bacterial DNA gyrase (Topoisomerase II) and topoisomerase IV, disrupting DNA replication in susceptible bacteria.
Pregnancy: Category C (US FDA). Topical corticosteroids, especially potent ones like Mometasone, should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Use should be limited in amount and duration. Avoid large areas or long-term use. Data on Miconazole and Nadifloxacin topical use in pregnancy is limited.
Driving: No known effects on driving ability.
| Warfarin and other Coumarin anticoagulants | Miconazole (systemic) can inhibit metabolism, increasing INR and risk of bleeding. Risk with topical use is low but documented. | Moderate |
| Oral Hypoglycemic Agents (Sulfonylureas like Glimepiride) | Miconazole may increase their serum levels, potentiating hypoglycemic effect. | Moderate |
| Phenytoin, Carbamazepine | Miconazole may increase their serum levels, leading to toxicity. | Moderate |
| CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin) | May increase systemic levels of Mometasone if absorbed. | Low |
| Other Topical Corticosteroids | Concomitant use increases cumulative steroid dose and risk of local and systemic adverse effects. | High |
Same composition (Miconazole (2% w/w) + Mometasone (0.1% w/w) + Nadifloxacin (1% w/w)), different brands: